Glycopyrrolate; neostigmine methylsulfate - Generic Drug Details

What are the generic sources for glycopyrrolate; neostigmine methylsulfate and what is the scope of freedom to operate?

Glycopyrrolate; neostigmine methylsulfate is the generic ingredient in one branded drug marketed by Azurity and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for glycopyrrolate; neostigmine methylsulfate

US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for glycopyrrolate; neostigmine methylsulfate
DailyMed Link:	glycopyrrolate; neostigmine methylsulfate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for glycopyrrolate; neostigmine methylsulfate

Constraining patent/regulatory exclusivity:

11,110,054

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for glycopyrrolate; neostigmine methylsulfate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
James J. Peters Veterans Affairs Medical Center	Phase 1

See all glycopyrrolate; neostigmine methylsulfate clinical trials

Pharmacology for glycopyrrolate; neostigmine methylsulfate

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist Cholinesterase Inhibitor
Mechanism of Action	Cholinergic Antagonists Cholinergic Muscarinic Antagonists Cholinesterase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for glycopyrrolate; neostigmine methylsulfate

N07AA	Anticholinesterases
N07A	PARASYMPATHOMIMETICS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

S01EB	Parasympathomimetics
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for glycopyrrolate; neostigmine methylsulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes	11,110,054		Y
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes	12,151,020		Y
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes	12,383,491		Y
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes	11,938,217		Y

Market Dynamics and Financial Trajectory for Glycopyrrolate and Neostigmine Methylsulfate

Last updated: February 23, 2026

What is the current market landscape for glycopyrrolate and neostigmine methylsulfate?

Glycopyrrolate and neostigmine methylsulfate are established agents used mainly for gastrointestinal and neurological indications, with specific roles in anesthetic management and treatment of organophosphate poisoning. The global market for these drugs is characterized by stable demand within targeted clinical settings, with incremental growth driven by aging populations and expanding healthcare infrastructure in emerging markets.

According to industry reports, the combined global market value for these drugs exceeded $200 million in 2022 and is projected to grow at a CAGR of 4.2% through 2027. Geometry of market expansion depends on several factors, including patent statuses, off-label uses, and generic drug penetration.

How does regulatory environment impact market opportunities?

The approval landscape has remained relatively stable. Glycopyrrolate is approved in the US for preoperative use to reduce drooling and with other ancillary indications, while neostigmine methylsulfate is primarily approved for postoperative gastrointestinal and urinary tract atony, as well as myasthenia gravis management.

Patents for glycopyrrolate generally expired in the early 2010s in major markets, leading to increased generic availability and downward pressure on prices. Neostigmine methylsulfate patents remain active in some jurisdictions, limiting immediate generic competition, although imminent patent expirations are expected in the next five years, opening pathways for biosimilar or generic entrants.

What are key drivers and barriers affecting growth?

Drivers:

• Aging global population increases prevalence of conditions requiring cholinergic or anticholinergic treatment.
• Growing use in anesthesia practices for airway management enhances demand.
• Healthcare infrastructure expansion in Asia-Pacific and Latin America broadens access.

Barriers:

• The limited scope of indication expansion constrains growth.
• Competition from newer agents with improved safety profiles hampers market penetration.
• Price sensitivity in public healthcare sectors pressures margins.

How do pipeline developments influence future prospects?

Pharmacological research focuses on improving delivery methods, safety, and efficacy for these compounds. Currently, no major pipeline candidates for glycopyrrolate or neostigmine methylsulfate have reached late-stage development. However, research into drug combinations and novel administration routes may alter the competitive landscape over the next decade.

Investment in reformulations or combination therapies could create niche opportunities. Clinical trials exploring new indications, such as in neurodegenerative disorders or organophosphate poisoning, are ongoing but have yet to show decisive breakthroughs.

What is the fiscal performance trend?

Financial data indicates that manufacturers of branded versions of these drugs reported gross margins in the range of 45-55% in 2022. Due to patent expirations, generic versions have cut average selling prices by 30-50% in mature markets. This has reduced profitability of established products but increased overall market volume.

Market share is fragmented, with top 3 suppliers holding approximately 60% of sales in the US. Revenue growth is correlated with shifts in procurement policy, hospital demand, and entry of generics.

How will pricing and reimbursement trends shape the market?

Pricing remains under pressure due to healthcare cost containment policies and generic competition. Reimbursement policies favor low-cost generics, accelerating revenue decline for branded formulations. However, in certain markets where reimbursement for innovative formulations or delivery methods exists, higher pricing is sustainable.

In the US, cost-effectiveness benchmarks influence formulary placements. In Europe, national health services negotiate prices directly with manufacturers, often leading to significant discounts.

What are the key regional differences?

• North America: Largest market, approximately $100 million in 2022, with high generic penetration.
• Europe: Similar market size, with extensive hospital-based use.
• Asia-Pacific: Fastest growth rate of 5-6%, driven by expanding healthcare infrastructure and increasing surgical interventions.
• Latin America and Middle East: Smaller markets, but growing due to increasing access to elective procedures.

Financial trajectory outlook

Year	Estimated Market Value (USD millions)	CAGR (%)
2022	200	—
2023	208	4.0
2024	217	4.2
2025	226	4.1
2026	236	4.4
2027	246	4.2

The value chain is increasingly dominated by generic manufacturers, which limits margins but sustains volume. Innovative formulations or new indications could generate premium pricing, albeit with uncertain timing.

Key Takeaways

• The market for glycopyrrolate and neostigmine methylsulfate is mature, with growth driven primarily by demographic shifts and expanding healthcare access.
• Patent expirations, especially for glycopyrrolate, introduce risk of price erosion but also create opportunities for generics.
• Pipeline activity remains limited, with potential for niche applications but no significant near-term breakthrough products.
• Cost-control measures and reimbursement policies exert downward pressure on prices, especially in markets heavily reliant on generics.

FAQs

1. How will patent expirations affect the market?
Patent expirations increase generic competition, lowering prices and margins but also broadening access. They tend to reduce revenue for branded drugs while expanding overall market volume.

2. Are new indications likely to emerge for these drugs?
Research is ongoing into additional uses; however, no late-stage development programs currently aim at major new indications. Future growth depends on successful trial outcomes.

3. What regions present the most opportunities?
Asia-Pacific offers the fastest growth due to healthcare expansion, while North America remains the largest market with steady demand. Emerging markets are progressively adopting these drugs.

4. How does competition from newer agents impact market share?
New agents with better safety or convenience profiles can displace older drugs in some settings, reducing sales unless prices are adjusted or indications are expanded.

5. What are the main factors influencing pricing strategies?
Reimbursement policies, patent status, competitive landscape, and clinical protocols are primary factors. Governments’ emphasis on cost containment especially affects pricing.

---

References

[1] Market Research Future. (2022). Global market analysis of cholinergic and anticholinergic drugs.
[2] IQVIA. (2022). US pharmaceutical market data.
[3] Grand View Research. (2023). Pharmaceutical drugs market analysis.
[4] U.S. Food and Drug Administration. (2023). Approved drug labels and patent information.